netFormulary

North East and North Cumbria
ICS Formulary

back

2 Cardiovascular system

02-12 Lipid-regulating drugs

Alirocumab

Formulary

Only approved for use in accordance with NICE guidance.

NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Evolocumab

Formulary

Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.

NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Icosapent ethyl Vazkepa^®

Formulary

998mg capsules
Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
- established cardiovascular disease (secondary prevention), defined as a history of any of the following:
  - acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
  - coronary or other arterial revascularisation procedures
  - coronary heart disease
  - ischaemic stroke
  - peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre

NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides

Inclisiran Leqvio^®

Formulary

284mg/1.5ml solution for injection pre-filled syringes
- Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE.

NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia

Links